501 filings
Page 20 of 26
8-K
z67v3551d8g4t4u9ee
17 Nov 14
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
12:00am
425
gk6 sximu
17 Nov 14
Business combination disclosure
12:00am
425
u8508dr3x4ub0z
17 Nov 14
Business combination disclosure
12:00am
SC TO-T/A
sz3gg0ntjqo5540bew
17 Nov 14
Third party tender offer statement (amended)
12:00am
8-K
8nf6yrnk0bgi l4tdn
12 Nov 14
Actavis Announces Planned Retirement of R. Todd Joyce
12:00am
8-K
y6si4uf clz
5 Nov 14
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
12:00am
8-K
v0de0njve1m6v
5 Nov 14
Regulation FD Disclosure
12:00am
SC TO-T/A
x2s3iw9oyi1b3w8jy 27
31 Oct 14
Third party tender offer statement (amended)
12:00am
SC TO-T/A
8lo1o natz
24 Oct 14
Third party tender offer statement (amended)
12:00am
CORRESP
iupy2 til
24 Oct 14
Correspondence with SEC
12:00am
SC TO-T
fyn4nk wcvqm
17 Oct 14
Third party tender offer statement
12:00am
SC TO-C
jwli3 ccvmrpg85tc
8 Oct 14
Information about tender offer
12:00am
8-K
f7s0pjtlxw bd56u8
8 Oct 14
Form of CVR Agreement
12:00am
SC TO-C
q52vteo
6 Oct 14
Information about tender offer
12:00am
8-K
8rz2qxwxf s2
6 Oct 14
Other Events
12:00am
8-K
i3vok9qf2oxbay z4
30 Sep 14
Regulation FD Disclosure
12:00am
8-K
4ogxh6lum q7rbt
8 Aug 14
Other Events
12:00am
8-K
83yym bhenock1
5 Aug 14
Regulation FD Disclosure
12:00am
8-K
zhu 65je08ls
5 Aug 14
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42
12:00am